0001193125-21-010914.txt : 20210218 0001193125-21-010914.hdr.sgml : 20210218 20210119090458 ACCESSION NUMBER: 0001193125-21-010914 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 CORRESP 1 filename1.htm Company Accel. Request

Dyne Therapeutics, Inc.

830 Winter Street

Waltham, MA 02451

January 19, 2021

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance, Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Abby Adams

 

Re:

Dyne Therapeutics, Inc.

Registration Statement on Form S-1

File No. 333-252194

Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Dyne Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-252194), so that it may become effective at 4:00 p.m. Eastern time on January 20, 2021, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request by telephone call to the staff of the U.S. Securities and Exchange Commission.

Please contact Stuart M. Falber of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Company, at (617) 526-6663, or in his absence, Scott Lunin at (212) 295-6388, to provide notice of effectiveness, or if you have any other questions regarding this matter.

[Remainder of Page Intentionally Left Blank]


Very truly yours,
DYNE THERAPEUTICS, INC.
By:  

/s/ Joshua Brumm

  Name: Joshua Brumm
  Title: President and Chief Executive Officer

Signature Page to Acceleration Request